ClinicalTrials.gov
ClinicalTrials.gov Menu

Vascular Endothelial Growth Factor Levels at Hysteroscopic Biopsies Which Taken From Recurrent Pregnancy Loss

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01735331
Recruitment Status : Completed
First Posted : November 28, 2012
Last Update Posted : August 7, 2015
Sponsor:
Information provided by (Responsible Party):
Bagcilar Training and Research Hospital

November 26, 2012
November 28, 2012
August 7, 2015
November 2012
August 2013   (Final data collection date for primary outcome measure)
The primary outcome measure of this study is to determine endometrial vascular endothelial growth factor levels in patient with Recurrent Pregnancy Loss [ Time Frame: 3 months ]
Same as current
Complete list of historical versions of study NCT01735331 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Vascular Endothelial Growth Factor Levels at Hysteroscopic Biopsies Which Taken From Recurrent Pregnancy Loss
Vascular Endothelial Growth Factor Levels at Hysteroscopic Biopsies Which Taken From Recurrent Pregnancy Loss
The aim of this study is determine vascular endothelial growth factor levels and angiogenesis/vascularity from hysteroscopic endometrial biopsies which taken from patients who has Recurrent Pregnancy Loss.The endometrial vascular endothelial growth factor levels will be measured by immunohistochemical staining methods due to office hysteroscopic endometrial biopsy after the menstruation at follicular phase of menstrual cycle.

This study is a prospective,observational,single-center study.Ethical approval was obtained from the Institutional Review Board.This study will be completed 30 patients with Habitual Abortus.

Endometrial vascular endothelial growth factor levels will be measured using Flk-1 / Kinase Domain Receptor / Vascular endothelial growth factor receptor-2, Ab-1 (Rabbit PAb), Vascular Endothelial Growth Factor (VEGF) Ab-7 (VG1), Cluster of Differentiation 34 (Endothelial Cell Marker) Ab-1 (QBEnd/10), Vascular endothelial growth factor receptor-1 (N-term) (FLT1) antibody kits. All assays will be performed according to the manufacturer's instructions.

Observational
Observational Model: Case Control
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample
The patients with Recurrent Pregnancy Loss
Recurrent Pregnancy Loss Without Current Pregnancy
Not Provided
  • VEGF level
    VEGF level in hysteroscopic endometrial biopsy of the patients with recurrent pregnancy loss.
  • control group
    Patients with Abnormal Uterine Bleeding
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
30
Same as current
August 2013
August 2013   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients with Recurrent Pregnancy Loss who accept to join the study.

Exclusion Criteria:

  • Patients whose age of <18 and >45
  • Patients with have any pregnancy.
Sexes Eligible for Study: Female
18 Years to 45 Years   (Adult)
No
Contact information is only displayed when the study is recruiting subjects
Turkey
 
 
NCT01735331
BEHGynObs-3
No
Not Provided
Not Provided
Bagcilar Training and Research Hospital
Bagcilar Training and Research Hospital
Not Provided
Principal Investigator: TANER A. USTA, M.D. Bagcilar Training and Research Hospital,Istanbul,Turkey.
Bagcilar Training and Research Hospital
August 2015